The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00911157 |
Recruitment Status
:
Completed
First Posted
: June 1, 2009
Results First Posted
: June 10, 2010
Last Update Posted
: November 23, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Thrombosis, Venous | Drug: Fondaparinux sodium Drug: unfractionated heparin (UFH) | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 39 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Deep Vein Thrombosis (DVT) |
Study Start Date : | June 2008 |
Actual Primary Completion Date : | November 2009 |
Actual Study Completion Date : | November 2009 |
Arm | Intervention/treatment |
---|---|
Experimental: Fondaparinux |
Drug: Fondaparinux sodium
The dose of Fondaparinux will be determined based on a subject's body weight (< 50 kg, 5 mg; 50 to 100 kg, 7.5 mg; >100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
Other Name: GSK576428
|
unfractionated heparin |
Drug: unfractionated heparin (UFH)
UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
|
- Percentage of Participants With Recurrent or New Symptomatic Venous Thromboembolism (VTE) [ Time Frame: From Day 1 to Day 90 (±7 days) ]VTE (pulmonary thromboembolism [PE] and/or deep vein thrombosis [DVT]) was adjudicated blindly by the Central Independent Adjudication Committee of Efficacy (CIACE).
- Percentage of Participants With Recurrent or New Symptomatic/Asymptomatic VTE (by Type) [ Time Frame: From Day 1 to Day 90 (±7 days) ]VTE (pulmonary thromboembolism [PE] and/or deep vein thrombosis [DVT]) was adjudicated blindly by the CIACE.
- Percentage of Participants With Perfusion Lung Scan Results Scored as Improved, no Change, or Worse Compared to Baseline [ Time Frame: Baseline, single day between Day 5 and Day 10 (the day when the medication [FPX or UFH] was finished /discontinued) (±1 day) ]Classifications of "Improved," "No change," or "Worse" were adjudicated blindly by the CIACE.
- Total Perfusion Score at Baseline and Mean Change From Baseline at Day 5-10 [ Time Frame: Baseline, single day between Day 5 and Day 10 (the day when the medication [FPX or UFH] was finished /discontinued) (±1 day) ]Change from baseline was calculated as the score on the day medication was finished/discontinued (anywhere from Day 5 to Day 10) minus the baseline score. The perfusion score (0: no perfusion; 0.25, 0.5, 0.75, 1: normal) in each of the six lobes of the lung was adjudicated blindly by the CIACE. Total perfusion score (r) was calculated as: r = (0.25 x right lower lobe) + (0.12 x right middle lobe) + (0.18 x right upper lobe) + (0.20 x left lower lobe) + (0.12 x lingula) + (0.13 x left upper lobe).
- Percentage of Participants With a Bleeding Event [ Time Frame: Initial treatment period (from the first dose of FPX/UFH to N days after the last dose of FPX/UFH; specified based on creatinine clearance [CLcr]; N=3, CLcr >=50 mL/min; N=4, 30 =< CLcr < 50 mL/min; N=9, CLcr < 30 mL/min). ]Bleeding events (major bleeding [clinically overt bleeding with fatality, location in a critical organ, a fall in hemoglobin >=2 grams (g)/deciliter (dL), or a transfusion >=2 units]; minor bleeding [clinically overt bleeding and not adjudicated as major bleeding], and no bleeding) were adjudicated blindly by the Central Independent Adjudication Committee of Safety (CIACS).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Confirmed diagnosis of acute proximal DVT based on contrast-enhanced Multi detector-row CT (MDCT) (not more than 10 days after the onset of the symptoms of DVT)
- Age:20 years
- Gender: No restriction
- Hospitalization status: Subjects who are able to stay at the hospital at least during the initial treatment period
- Written informed consent from the subject him/herself or his/her legally acceptable representative. Written informed consent from the subject's legally acceptable representative must be obtained if the subject is incapable of giving consent
Exclusion Criteria:
- Symptomatic PE
- Requirement for surgical thrombectomy, catheter intervention and thrombolytic therapy for the current DVT
- Subjects (for example, with free-floating thrombus in the femoral vein or ilium by MDCT at screening) for whom insertion of inferior vena cava filter is indicated or subjects in whom inferior vena cava filter is present
- Anticoagulant therapy for at least 24 hours to treat the current episode prior to entry into the study
- Active, clinically significant bleeding
- Thrombocytopenia (platelet count <10×10⁴/µL at screening)
- Concurrent conditions with bleeding risk (e.g., ulcer of the gastrointestinal tract, diverticulitis of the gastrointestinal tract, colitis, acute bacterial endocarditis, severe hypertension, or severe diabetes) or bleeding tendency
- Severe hepatic disorder
- Known hypersensitivity to heparin, low-molecular-weight heparin (LMWH) or warfarin
- Previous history of cerebral hemorrhage
- Brain, spinal, or ophthalmological surgery within 3 months prior to entry into this study
- Previous history of Heparin-induced thrombocytopenia
- Patients for whom anticoagulant therapy is contraindicated or who cannot be taken off anticoagulant therapy due to coexistent condition (e.g. prosthetic heart valve implant)
- Severe renal disorder (serum creatinine >2.0 mg/dL [180 µmol/L] at screening) in a well hydrated subject
- QT interval prolonged (QT interval corrected by Bazett's formula [QTcB] ≥450 msec; for patients with bundle branch block QTcB ≥480 msec) at screening
- Documented hypersensitivity to contrast media
- Use of any contraindicated drug that cannot be combined with the injection of contrast medium [e.g., antihyperglycemics, such as biguanides (metformin hydrochloride, buformin hydrochloride)]
- Participation in any other therapeutic drug study or a clinical study within 6 months prior to entry into this study
- Previous participation in a study of GSK576428 [Fondaparinux Sodium; including the studies of Org31540/SR90107A (ex-project code)] or previous exposure to the therapeutic dose of GSK576428
- Drug or alcohol abuse
- Systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg
- Recent surgery within 3 days prior to entry into the study
- Life expectancy <3 months
- Pregnant women, nursing mothers, women who may be pregnant, or women contemplating pregnancy during the study period
- Others whom the investigator or subinvestigator considers not eligible for the study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00911157
Japan | |
GSK Investigational Site | |
Aichi, Japan, 440-8510 | |
GSK Investigational Site | |
Fukuoka, Japan, 802-8555 | |
GSK Investigational Site | |
Gunma, Japan, 370-0829 | |
GSK Investigational Site | |
Gunma, Japan, 371-8511 | |
GSK Investigational Site | |
Hiroshima, Japan, 720-8520 | |
GSK Investigational Site | |
Hiroshima, Japan, 739-0651 | |
GSK Investigational Site | |
Hokkaido, Japan, 006-8555 | |
GSK Investigational Site | |
Hokkaido, Japan, 060-8543 | |
GSK Investigational Site | |
Hokkaido, Japan, 060-8648 | |
GSK Investigational Site | |
Hyogo, Japan, 654-0155 | |
GSK Investigational Site | |
Ibaraki, Japan, 305-8576 | |
GSK Investigational Site | |
Ibaraki, Japan, 311-3193 | |
GSK Investigational Site | |
Kagoshima, Japan, 892-0853 | |
GSK Investigational Site | |
Kanagawa, Japan, 245-8575 | |
GSK Investigational Site | |
Kumamoto, Japan, 860-0008 | |
GSK Investigational Site | |
Kumamoto, Japan, 860-8556 | |
GSK Investigational Site | |
Mie, Japan, 514-8507 | |
GSK Investigational Site | |
Nagano, Japan, 399-0021 | |
GSK Investigational Site | |
Nagasaki, Japan, 859-3615 | |
GSK Investigational Site | |
Niigata, Japan, 951-8520 | |
GSK Investigational Site | |
Okayama, Japan, 701-1192 | |
GSK Investigational Site | |
Shizuoka, Japan, 430-8558 | |
GSK Investigational Site | |
Shizuoka, Japan, 438-8550 | |
GSK Investigational Site | |
Tokyo, Japan, 113-8655 |
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
Additional Information:
Study Data/Documents: Dataset Specification

For additional information about this study please refer to the GSK Clinical Study Register

For additional information about this study please refer to the GSK Clinical Study Register

For additional information about this study please refer to the GSK Clinical Study Register
Publications:
Responsible Party: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00911157 History of Changes |
Other Study ID Numbers: |
111436 |
First Posted: | June 1, 2009 Key Record Dates |
Results First Posted: | June 10, 2010 |
Last Update Posted: | November 23, 2016 |
Last Verified: | October 2016 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site. |
Keywords provided by GlaxoSmithKline:
Pulmonary thromboembolism contrast-enhanced MDCT Deep Vein Thrombosis Fondaparinux sodium |
Additional relevant MeSH terms:
Thrombosis Venous Thrombosis Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Calcium heparin Fondaparinux PENTA Heparin |
Anticoagulants Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Factor Xa Inhibitors Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors |